Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients
Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients
复制标题
DOI：
10.1016/j.breast.2006.12.011
复制
发表时间：
2007-06-01
期刊：
影响因子：
3.9
通讯作者：
Shao, Zhi-Ming
中科院分区：
文献类型：
--
作者：
Yu, Ke-Da;Liu, Guang-Yu;Shao, Zhi-Ming
雌激素受体（ER）状态可以预测内分泌治疗的疗效。然而，孕激素受体（PgR）的预测意义在辅助设置是有争议的。回顾758例ER+乳腺癌患者3 ~ 5年的辅助他莫昔芬（TAM）治疗记录，评价ER+/PgR+组和ER+/PgR-组中PgR对TAM治疗的预测价值。在平均40个月的随访中，两组在无病生存（DFS）方面没有显著差异。在STEPP分析ER+/PgR-组和ER+/PgR+组年龄对DFS影响趋势的基础上，我们将ER+患者按年龄分为< 45岁、45-60岁和>= 60岁三层。两组患者在< 45层和45-60层的DFS和总生存期（OS）差异无统计学意义。相比之下，ER+/PgR-组在>= 60层的DFS （P = 0.0484）和OS （P = 0.0009）预后较差。结果表明，PgR状态可能是老年ER+患者从辅助TAM中获得的DFS和OS获益的预测因素。这应该考虑到老年ER+/PgR-患者往往对TAM有抵抗力。(c) 2007 Elsevier Ltd.版权所有。
Estrogen receptor (ER) status can predict the efficacy of endocrine therapy. However, the predictive significance of the progesterone receptor (PgR) is controversial in an adjuvant setting. Records of 758 ER+ breast cancer patients who received adjuvant tamoxifen (TAM) for 3-5 years were reviewed to evaluate the predictive value of PgR for TAM treatment in ER+/PgR+ and ER+/PgR- groups. By a median of 40 months' follow-up, there was no significant difference between the two groups with regard to disease-free-survival (DFS). On the basis of STEPP analysis showing the tendency of age effect on DFS in both the ER+/PgR- and ER+/PgR+ groups, we classified the ER+ patients into three strata by age (< 45, 45-60, and >= 60 years). There was no significant difference in DFS and overall survival (OS) between the two groups in the < 45 stratum and the 45-60 stratum. In contrast, the ER+/PgR- group had a worse prognosis in the >= 60 stratum with regard to both DFS (P = 0.0484) and OS (P = 0.0009). The results suggest that PgR status might be a predictive factor of benefit to be gained from adjuvant TAM for older ER+ patients with regard to DFS and OS. This should take into account older ER+/PgR- patients who tend to be resistant to TAM. (c) 2007 Elsevier Ltd. All rights reserved.